. 2021 Apr 20;20:15330338211010134. doi: 10.1177/15330338211010134

Table 1.

Summary of the Studies and Characteristics of the Patients Included in the Review.

First author, year published (reference)	No. of patients included/analyzed	Diagnosis stage according to FIGO	Histology	Drug/route of administration	Response according to RECIST after 1 month
First author, year published (reference)	No. of patients included/analyzed	Diagnosis stage according to FIGO	Histology	Drug/route of administration	CR (No. of patients/%)	PR (No. of patients/%)
Pellegrino, 2016¹⁹	10/10	Stage IB 40% Stage II 40% Stage IIIA 10% Paget cancer 10%	Recurrence of vulvar cancer	i.v. bleomycin	2 (20%)	4 (40%)
Perrone, 2013²⁰	9/8	Stage IA 11% Stage IB 11% Stage II 33% Stage IIIA 33% Stage IIIB 11%	Vulvar SCC	i.v. bleomycin	5 (62.5%)	1 (12.5%)
Perrone, 2015²¹	25/25	Stage IA 20% Stage IB 32% Stage IIA 32% Stage IIIA 8% Stage IIIB 4% Stage IV 4%	Vulvar SCC	i.v. bleomycin	13 (52%)	7 (28%)
Perrone, 2018²²	9/9	Stage I-II 100%	Vulvar SCC	i.v. bleomycin	1 (11%)	6 (67%)
Sersa, 1999²³	1/1	/	Dedifferentiated papillary ovarian adenocarcinoma	i.t. cisplatin	/	/
Schiavi, 2017²⁴	1/1	Stage II	Endometrial carcinoma	i.v. bleomycin	/	1*

Abbreviations: SCC, squamous cell carcinoma; i.v., intra venous; i.t., intra tumoral administration.

* Response 4 months post electrochemotherapy.